Coronavirus

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.

Evaluating nirmatrelvir–ritonavir over 5-10 days for post-exposure prophylaxis revealed no reduction in symptomatic SARS-CoV-2 infections compared to placebo among asymptomatic adults.

A large study from the Veterans Affairs shows an association between being unvaccinated and a greater incidence rate of Long COVID.

The disconnect between evolving science and medical communication has left people confused about how to interpret public health information, and provided an opportunity for vaccine deniers and politicians to give disinformation on COVID-19.

Emily Hadley highlights study findings showing a higher incidence of Long COVID following initial infections compared to reinfections, particularly during the Omicron period among 3 million patients.

The company acquired rights from CureVac to develop vaccines for influenza and COVID-19 using the mRNA platform.

The Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases (NFID) both weigh in on the evolving summer COVID-19 season, and strategies for prevention.

A clinical stage company, NanoViricides, is moving forward with their investigational drug, NV-387, into phase 2 clinical trials to examine treatment for RSV, influenza, COVID-19.

Matthew M Davis, MD, MAPP elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

Boosted neutralization against variant XBB15 fades within 3 months post-first booster in transplant recipients but improves with a second, hybrid immunity enhances, suggesting 3-6 month boost intervals for solid organ transplant recipients.

Novavax, Inc has unveiled promising results regarding its JN1 COVID-19 vaccine's efficacy against emerging virus variants, including KP2 and KP3.

Biosurveillance has evolved beyond biodefense, emphasizing a comprehensive network to detect and counter biological threats.

During today's CDC Advisory Committee on Immunization Practices (ACIP) meeting, committee members voted to recommend the FDA-authorized 2024-2025 COVID-19 vaccines for individuals aged 6 months and older. Additionally, they reaffirmed the existing influenza vaccination guidelines for the 2024-2025 season.

Those individuals who received older versions of vaccines did not see significantly reduced risks of severe COVID-19 outcomes.

Research presented at ASHP 2024 found that concerns around the safety of COVID-19 vaccines and the credibility of information from public health authorities were the biggest drivers of vaccine hesitancy during the COVID-19 pandemic.

Jerry Krishnan, MD, PhD, working with NASEM, examines the multifaceted challenges of defining Long COVID as they introduce a unified definition for this persistent condition.

Study reveals an increase in hospital admissions and the need for advanced respiratory support, particularly among older, healthier children.

The state's attorney general filed the lawsuit against Pfizer for its ‘misleading statements’ about the vaccine.

In response to evolving data on SARS-CoV-2 strains and rising COVID-19 cases, the FDA advises vaccine manufacturers to explore incorporating the KP2 strain into the upcoming 2024-2025 COVID-19 vaccine formula.

Leveraging Evie Ring technology, the collaboration seeks to enhance understanding and develop strategies for managing these illnesses.

A recently published secondary analysis sought to evaluate the risk of MACE in those patients who received one or two doses of the COVID-19 following acute coronary syndromes.

With no observed mortality or adverse outcomes, this research sheds light on effective treatments for combating the pandemic in younger populations.

Exact estimates of hospitalization and fatality rates for SARS-CoV-2 are rare among populations without previous exposure, particularly within demographic subgroups.

The company announced data this morning for its investigational mRNA-1083 vaccine and plans to continue collecting data and working towards submitting a Biological License Application (BLA) for it.

A newly published study suggests that a 15-day regimen, while safe, did not statistically separate from a placebo comparator group in main outcomes for PASC of SARS-CoV-2 infection.

Although there is a rise in the FLiRT family of mutations, the committee decided to seek protection against the older strain.

While much attention has been focused on the immediate risks of the virus during pregnancy, this study is focused on what happens to pregnant individuals after they have had COVID-19.

Deaths varied greatly depending on the age group, with the oldest population having the highest rates.

Research reveals a surge in pressure ulcers and in-hospital mortality rates during peak pandemic periods, prompting calls for strategies to safeguard care quality.